Posts by Noëlle Aubert

Awakening “ghosts” in patients with Parkinson’s   EPFL scientists are developing a completely new “brain stress test” for evaluating the mental status of patients with Parkinson’s disease, the second most prevalent neurodegenerative disease worldwide. It involves awakening the “ghosts” hidden in specific networks of the brain to predict the onset of hallucinations. “We’re developing something…

Introduction of AI suite in Swiss medical institutions   South Korean Medical AI trailblazer, VUNO, and Swiss medical distribution company, HealthCare Konnect (HCK), announce the signature of a distribution agreement to introduce VUNO’s AI solutions to healthcare institutions in Switzerland, for the sake of clinical workflow optimisation and efficient medical diagnosis. With diagnostic errors being…

3 Biopôle-based companies are striving to find innovation solutions   CHUV-NeuroTech, ND BioSciences & Gondola Medical Technologies , 3 Biopôle-based companies are striving to find innovation solutions to help Parkinson’s patients. Parkinson’s disease affects around 0.2% of the worldwide population, and up to 1% of those aged 60 years and above. Precise data from the canton of…

Partnership on the analysis of SARS-COV-2 virus in saliva using the RT-PCR method   CoreMedica Europe a Swiss biotechnology company based in Geneva and the Swiss Integrative Center for Human Health (SICHH), a competence centre based in Fribourg, announced  their partnership on the analysis of SARS-COV-2 virus in saliva using the RT-PCR method, destined to both individuals…

A brand new tool is available to map the organisational impacts    Innovation in health care is shaking up and revolutionising patient care and the organisation of care.  A brand new tool is available to map the organisational impacts of these innovations. This new innovative tool for the evaluation of healthcare technologies (HT) has been…

FDA Approval of ZYNLONTA™ in Relapsed or Refractory Diffuse Large B-Cell Lymphoma   ADC Therapeutics SA announced that the Food and Drug Administration (FDA) has approved ZYNLONTA™ (loncastuximab tesirine-lpyl) for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell…

An attractive, dynamic & ever-growing life sciences ecosystem   Biotechnology companies based in Switzerland have experienced record investments in the pandemic year 2020. The western Switzerland region, home to the “Health Valley”, ranks second nationally in the financing of private biotech companies. According to the 2021 edition of the Swiss Biotech Report, the Swiss biotech sector…

An injectable gel that can attach to various kinds of soft internal tissues    EPFL scientists have developed an injectable gel that can attach to various kinds of soft internal tissues and repair tears resulting from an accident or trauma.  Our soft tissues can be torn during different kind of accidents. And surgeons can have…

A new hub for biologics R&D in Western Switzerland   On 1 April 2021, the research-driven biopharmaceutical group Ferring Pharmaceuticals opened a state-of-the-art innovation centre at Biopôle (Lausanne, Switzerland), bringing a new hub for biologics research and development to the vibrant life sciences campus near Lausanne. The Ferring Biologics Innovation Centre targets unmet medical needs…

In 2020, 85 new foreign companies set up shop in Western Switzerland, supported by Greater Geneva Bern area (GGBa) and the cantonal economic development agencies. They plan to create 772 jobs over the next three years, with the largest contributions coming from Life Sciences (227) and Information and Communication Technologies (184). This robust performance is a…